Kelyniam Global Reports Q3 2025 Financial Results Amidst Market Challenges

Kelyniam Global, Inc. (OTC: KLYG), recognized as a leader in custom cranial and craniofacial implants, has disclosed its financial performance for the third quarter ending on September 30, 2025. The company experienced some downturns but remains optimistic about its future trajectory.

Financial Highlights

According to the financial report, Kelyniam reported a year-to-date revenue of $2,186,491, indicating a decrease of 12.3% when compared to $2,492,607 from the same quarter last year. The gross profit also declined by 13.3%, falling to $1,695,496, a significant change attributed primarily to revenue headwinds. Despite lower profits, stable material costs helped mitigate the losses somewhat.

Additionally, the operating loss for the quarter stood at $(162,373), in contrast to an operating income of $273,248 reported in Q3 2024. This shift reflects heightened investments in sales support and regulatory expenses tied to the company's new product, Vestakeep®.

CEO Insights

Ross Bjella, the CEO of Kelyniam Global, addressed the revenue challenges, stating, “Sales have faced headwinds this year from a slow distributor ramp-up and temporary market share shifts, but through Q3, we're steadily catching up to 2024 levels and building a stronger foundation for sustainable growth.” He expressed confidence in the cranial implant market's potential, as projections indicate an expansion from $1.43 billion in 2024 to over $1.5 billion in 2025. Bjella commented on the company's strategic move to enlist more distributors in untapped markets, aiming to capitalize on the rising demand for quick-turnaround, custom solutions.

Strategic Developments

Kelyniam’s Q3 2025 financial report also highlights key strategic developments:

1. FDA Approval for Vestakeep®: The company received 510(k) clearance for its innovative resorbable bi-calcium phosphate implant, thus expanding its offerings into regenerative applications and targeting areas of unmet need in craniofacial reconstruction.
2. Hospital Approvals Pipeline: The Kelyniam product line is currently undergoing evaluation at six major U.S. hospitals, which include two Level 1 trauma centers. Successful approvals could yield an additional $500,000+ in annual recurring revenue.
3. OTCID Status Uplift: Kelyniam has achieved OTCID status on the OTC Markets Group Platform, reflecting the company's dedication to financial transparency and compliance in its operations.

Full Financial Disclosure

For those interested in a more comprehensive view of Kelyniam's performance, the complete unaudited financial results for Q3 2025, ornate with detailed segment breakdowns and cash flow statements, are accessible on the company's official website at www.kelyniam.com.

About Kelyniam Global

Kelyniam Global specializes in the design, manufacturing, and distribution of custom cranial and craniofacial implants. The company is well-known for its rapid 24-48 hour delivery service, thereby establishing partnerships with surgeons, hospitals, and payors to enhance clinical outcomes while managing costs efficiently within the realm of neurosurgery. To learn more about Kelyniam Global, visit www.kelyniam.com.

Forward-Looking Statements

This announcement incorporates forward-looking statements as defined under relevant laws, covering projections for revenue growth, distributor expansion, and effects influenced by new partnerships and clearances. Given the inherent risks—such as competitive market dynamics, regulatory bottlenecks, and variability with distributor performances—actual outcomes may materially differ from what's anticipated. Kelyniam maintains its obligation to update statements only as mandated under applicable regulations.